Literature DB >> 20349065

Rituximab and leflunomide for Wegener's granulomatosis: a long-term follow-up.

J C Henes, L Kanz, I Koetter.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20349065     DOI: 10.1007/s00296-010-1462-x

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


× No keyword cloud information.
  5 in total

1.  Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.

Authors:  R Stasi; E Stipa; G Del Poeta; S Amadori; A C Newland; D Provan
Journal:  Rheumatology (Oxford)       Date:  2006-04-21       Impact factor: 7.580

2.  Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.

Authors:  K G C Smith; R B Jones; S M Burns; D R W Jayne
Journal:  Arthritis Rheum       Date:  2006-09

3.  A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.

Authors:  David Jayne; Niels Rasmussen; Konrad Andrassy; Paul Bacon; Jan Willem Cohen Tervaert; Jolanta Dadoniené; Agneta Ekstrand; Gill Gaskin; Gina Gregorini; Kirsten de Groot; Wolfgang Gross; E Christiaan Hagen; Eduardo Mirapeix; Erna Pettersson; Carl Siegert; Alberto Sinico; Vladimir Tesar; Kerstin Westman; Charles Pusey
Journal:  N Engl J Med       Date:  2003-07-03       Impact factor: 91.245

4.  Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group.

Authors:  C A Stegeman; J W Tervaert; P E de Jong; C G Kallenberg
Journal:  N Engl J Med       Date:  1996-07-04       Impact factor: 91.245

5.  Rituximab for treatment-resistant extensive Wegener's granulomatosis--additive effects of a maintenance treatment with leflunomide.

Authors:  J C Henes; J Fritz; S Koch; R Klein; M Horger; T Risler; L Kanz; I Koetter
Journal:  Clin Rheumatol       Date:  2007-05-15       Impact factor: 2.980

  5 in total
  1 in total

Review 1.  [Established medications : new areas of application].

Authors:  I Kötter; J C Henes
Journal:  Z Rheumatol       Date:  2013-11       Impact factor: 1.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.